30
Participants
Start Date
October 3, 2018
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2027
Radiation combined with immunotherapy
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
RECRUITING
University Health Network, Princess Margaret Cancer Centre, Toronto
University Health Network, Toronto
OTHER